OpenAI-Linked Biotech Startup Lands $130M to Reinvent Drug Design
Biotech startup Chai Discovery raised $130 million in a Series B round at a $1.3 billion valuation to advance AI-driven drug discovery.
Biotech startup Chai Discovery raised $130 million in a Series B round at a $1.3 billion valuation to advance AI-driven drug discovery.
Thrive Capital appointed former Palantir executive Jim Siders as CEO of Shield Technology Partners, its AI-focused IT services platform.
OpenAI invests in Thrive Holdings, embedding teams into its portfolio companies to accelerate AI adoption. The move deepens OpenAI’s circular dealmaking strategy with partners that also invest in it.
OpenAI has completed a secondary share sale worth $6.6 billion, letting current and former employees sell stock at a new $500 billion valuation — a milestone in the company’s funding strategy.